CN107208061B - γδ T细胞扩增方法 - Google Patents

γδ T细胞扩增方法

Info

Publication number
CN107208061B
CN107208061B CN201580072217.6A CN201580072217A CN107208061B CN 107208061 B CN107208061 B CN 107208061B CN 201580072217 A CN201580072217 A CN 201580072217A CN 107208061 B CN107208061 B CN 107208061B
Authority
CN
China
Prior art keywords
cells
expanded
cell
tgf
γδt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580072217.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107208061A (zh
Inventor
约翰·马赫
安娜·卡特里娜·帕伦特佩雷拉普里
理查德·埃斯蒙德·比特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of CN107208061A publication Critical patent/CN107208061A/zh
Application granted granted Critical
Publication of CN107208061B publication Critical patent/CN107208061B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580072217.6A 2014-12-05 2015-12-04 γδ T细胞扩增方法 Active CN107208061B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1421716.0A GB201421716D0 (en) 2014-12-05 2014-12-05 Cell expansion procedure
GB1421716.0 2014-12-05
PCT/GB2015/053713 WO2016087871A1 (en) 2014-12-05 2015-12-04 Gammadelta t cell expansion procedure

Publications (2)

Publication Number Publication Date
CN107208061A CN107208061A (zh) 2017-09-26
CN107208061B true CN107208061B (zh) 2025-11-18

Family

ID=52425560

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580072217.6A Active CN107208061B (zh) 2014-12-05 2015-12-04 γδ T细胞扩增方法

Country Status (13)

Country Link
US (5) US10557117B2 (https=)
EP (2) EP3696263A1 (https=)
JP (1) JP6802159B2 (https=)
KR (1) KR102686005B1 (https=)
CN (1) CN107208061B (https=)
AU (1) AU2015356788B2 (https=)
CA (1) CA2969783C (https=)
DK (1) DK3227435T3 (https=)
GB (1) GB201421716D0 (https=)
MX (1) MX392057B (https=)
RU (1) RU2017121191A (https=)
WO (1) WO2016087871A1 (https=)
ZA (1) ZA201704499B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
KR102032354B1 (ko) * 2016-11-11 2019-10-16 가톨릭대학교 산학협력단 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108588023B (zh) 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
TW202020145A (zh) 2018-07-13 2020-06-01 國立大學法人京都大學 γδＴ細胞的製造方法
CA3114292A1 (en) * 2018-09-27 2020-04-02 Phosphogam, Inc. Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
SG11202104692VA (en) * 2018-11-08 2021-06-29 In8Bio Inc Compositions and methods for treating cancer
CN110184240B (zh) * 2019-06-13 2020-11-20 上海市肺科医院 一种高效扩增活化Vγ2Vδ2 T细胞增强其抗结核活性的方法
CA3162755A1 (en) 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
US11999968B2 (en) 2021-10-22 2024-06-04 Fullhope Biomedical Co., Ltd Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用
JP2025064863A (ja) * 2023-10-06 2025-04-17 株式会社マイオリッジ Ｔ細胞の培養方法
JP7725011B1 (ja) * 2024-02-01 2025-08-19 ミヤリサン製薬株式会社 Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物
CN120924492B (zh) * 2025-10-15 2026-03-03 瑞因细胞工程科技(广州)有限公司 一种脐血来源γδT细胞的体外诱导组合物及培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103436492A (zh) * 2013-08-02 2013-12-11 北京赛诺泰生物科技有限公司 通过无血清培养扩增活化淋巴细胞的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7256498A (en) 1997-04-25 1998-11-24 Wistar Institute Of Anatomy And Biology, The Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof
AU747767B2 (en) * 1997-11-05 2002-05-23 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
ATE421573T1 (de) * 1998-11-04 2009-02-15 Therapure Biopharma Inc Verfahren zur herstellung von gamma delta t zellen
US20030157060A1 (en) * 2000-04-03 2003-08-21 Bell David N Production of tcr gamma delta t cells
FR2836483B1 (fr) 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
EP1426052B1 (en) 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
EP1720567A2 (en) 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DE602005022728D1 (de) * 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
AU2006272647A1 (en) 2005-07-25 2007-02-01 Therimunex Pharmaceuticals, Inc. Peptidyl diacylglycerides
WO2008059052A1 (en) * 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
WO2008129874A1 (ja) * 2007-04-13 2008-10-30 Medinet Co., Ltd. 腫瘍細胞の標的化方法、及びその用途
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
WO2009131730A2 (en) 2008-01-31 2009-10-29 University Of Iowa Research Foundation IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
US8962313B2 (en) * 2008-07-01 2015-02-24 Medinet Co., Ltd. Method for the simultaneous induction of CTL and γδT cell
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012131419A1 (en) * 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
CN103436493B (zh) * 2013-08-29 2016-02-03 浙江大学 雷帕霉素诱导调节性γδT细胞的培养方法
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103436492A (zh) * 2013-08-02 2013-12-11 北京赛诺泰生物科技有限公司 通过无血清培养扩增活化淋巴细胞的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cutting Edge: TGF-β1 and IL-15 Induce FOXP3+ γδ Regulatory T Cells in the Presence of Antigen Stimulation;Rita Casetti等;《The Journal of Immunology》;20090915;第183卷(第6期);摘要，图1A，图1C *
Rita Casetti等.Cutting Edge: TGF-β1 and IL-15 Induce FOXP3+ γδ Regulatory T Cells in the Presence of Antigen Stimulation.《The Journal of Immunology》.2009,第183卷(第6期),摘要，第3574页右栏第2-3段，图1A，图1C. *
Vγ9Vδ2 T细胞对人急性髓系白血病细胞的杀伤作用及机理研究;吴康妮;《中国博士学位论文全文数据库医药卫生科技辑》;20140315(第3期);第109页第1段 *
吴康妮.Vγ9Vδ2 T细胞对人急性髓系白血病细胞的杀伤作用及机理研究.《中国博士学位论文全文数据库医药卫生科技辑》.2014,(第3期),摘要第VII页，第62页倒数第1段，第84页倒数第1段，第85页第2段，第106页倒数第1段，第109页第1段，图1.9，图1.10，图1.11. *

Also Published As

Publication number Publication date
EP3696263A1 (en) 2020-08-19
RU2017121191A3 (https=) 2019-07-29
AU2015356788A1 (en) 2017-07-13
GB201421716D0 (en) 2015-01-21
US11566222B2 (en) 2023-01-31
CA2969783C (en) 2023-08-01
CA2969783A1 (en) 2016-06-09
MX392057B (es) 2025-03-21
US20200123502A1 (en) 2020-04-23
US10557117B2 (en) 2020-02-11
ZA201704499B (en) 2019-09-25
US20170342381A1 (en) 2017-11-30
RU2017121191A (ru) 2019-01-10
US20230323298A1 (en) 2023-10-12
AU2015356788B2 (en) 2021-09-30
KR20170084337A (ko) 2017-07-19
US20200140816A1 (en) 2020-05-07
US20250092364A1 (en) 2025-03-20
JP2017537625A (ja) 2017-12-21
CN107208061A (zh) 2017-09-26
WO2016087871A1 (en) 2016-06-09
MX2017007214A (es) 2018-01-30
EP3227435B1 (en) 2020-01-29
KR102686005B1 (ko) 2024-07-17
JP6802159B2 (ja) 2020-12-16
EP3227435A1 (en) 2017-10-11
DK3227435T3 (da) 2020-05-04

Similar Documents

Publication Publication Date Title
CN107208061B (zh) γδ T细胞扩增方法
Van Acker et al. Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
JP5792622B2 (ja) ナチュラルキラー細胞の製造方法
JP2023123437A (ja) ガンマデルタｔ細胞およびその使用
US20140073050A1 (en) Method for activation treatment of antigen-presenting cell
KR101923848B1 (ko) 면역세포 함유 조성물의 제조방법 및 암 치료용 조성물
US11473059B2 (en) Method for enrichment and expansion of virus antigen-specific T cells
Choi et al. γδ T cells cultured with artificial antigen-presenting cells and IL-2 show long-term proliferation and enhanced effector functions compared with γδ T cells cultured with only IL-2 after stimulation with zoledronic acid
KR20210079381A (ko) Ciml nk 세포 및 이를 위한 방법(ciml nk cells and methods therefor)
Tsuji-Takayama et al. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT
JP7119076B2 (ja) Ｎｋ細胞培養用組成物、及びそれを利用してｎｋ細胞を培養する方法
CN117402912A (zh) 扩增t细胞群的方法
Kim et al. Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly (I: C) enhances migratory and T cell stimulatory capacity
HK40100476A (zh) 扩增t细胞群的方法
D. Kühnöl et al. Lenalidomide in an in vitro dendritic cell model for malignant gliomas
Hwu et al. of June 13, 2013.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20360212